A hepatitis C-vírus-fertőzés egészségügyi jelentősége világszerte kiemelkedő, a világ lakosságának 3%-a fertőzött. Idült hepatitis C-fertőzöttek körülbelül 50%-ában alakul ki extrahepaticus betegség, amely a betegek kilátásait, mortalitását rontja. Kialakulásuk hátterében részben krioglobulinok képződése, immunmechanizmusok, valamint a vírus direkt hatásai állhatnak. A szerzők összefoglalják a hepatitis C-vírus-fertőzéssel összefüggő szervi érintettségeket, valamint a kezelés lehetőségeit. Közleményükkel a társszakmák figyelmét kívánják felhívni a fertőzés sokszínűségére, ezzel segítve a kórkép felismerését a hatékony direkt antivirális készítmények időszakában. Orv. Hetil., 2017, 158(16), 603–612.
Wong, J. B.: Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics, 2006, 24(7), 661–672.
Perz, J. F., Armstrong, G. L., Farrington, L. A., et al.: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol., 2006, 45(4), 529–538.
Alter, M. J.: Epidemiology of hepatitis C virus infection. World J. Gastroenterol., 2007, 13(17), 2436–2441.
Ali, A., Zein, N. N.: Hepatitis C infection: a systemic disease with extrahepatic manifestations. Cleve. Clin. J. Med., 2005, 72(11), 1005–1019.
Pascual, M., Perrin, L., Giostra, E., et al.: Hepatitis C virus in patients with cryoglobulinemia type II. J. Infect. Dis., 1990, 162(2), 569–570.
Galossi, A., Guarisco, R., Bellis, L., et al.: Extrahepatic manifestations of chronic HCV infection. J. Gastrointestin. Liver Dis., 2007, 16(1), 65–73.
Zignego, A. L., Brechot, C.: Extrahepatic manifestations of HCV infection: facts and controversies. J. Hepatol., 1999, 31(2), 369–376.
Tampaki, M., Koskinas, J.: Extrahepatic immune related manifestations in chronic hepatitis C virus infection. World J. Gastroenterol., 2014, 20(35), 12372–12380.
Yang, D. H., Ho, L. J., Lai, J. H.: Useful biomarkers for assessment of hepatitis C virus infection-associated autoimmune disorders. World J. Gastroenterol., 2014, 20(11), 2962–2970.
Younossi, Z., Park, H., Henry, L., et al.: Extrahepatic manifestations of hepatitis C: A meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology, 2016, 150(7), 1599–1608.
Khattab, M. A., Eslam, M., Alavian, S. M.: Hepatitis C virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of hepatitis C virus infection. Hepat. Mon., 2010, 10(4), 258–269.
Ozkok, A., Yildiz, A.: Hepatitis C virus associated glomerulopathies. World J. Gastroenterol., 2014, 20(24), 7544–7554.
Gill, K., Ghazinian, H., Manch, R., et al.: Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol. Int., 2016, 10(3), 415–423.
Ferri, C.: Mixed cryoglobulinemia. Orphanet J. Rare Dis., 2008, 3, 25.
Ferri, C., Greco, F., Longombardo, G., et al.: Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum., 1991, 34(12), 1606–1610.
Sene, D., Ghillani-Dalbin, P., Thibault, V., et al.: Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus. J. Rheumatol., 2004, 31(11), 2199–2206.
Ragab, G., Hussein, M. A.: Vasculitic syndromes in hepatitis C virus: A review. J. Adv. Res., 2017, 8(2), 99–111.
Sautto, G., Mancini, N., Clementi, M., et al.: Molecular signatures of hepatitis C virus (HCV)-induced type II mixed cryoglobulinemia (MCII). Viruses, 2012, 4(11), 2924–2944.
Cohen, S. J., Pittelkow, M. R., Su, W. P.: Cutaneous manifestations of cryoglobulinemia: clinical and histopathologic study of seventy-two patients. J. Am. Acad. Dermatol., 1991, 25(1), 21–27.
Tang, L., Marcell, L., Kottilil, S.: Systemic manifestations of hepatitis C infection. Infect. Agent. Cancer, 2016, 11, 29.
Misiani, R., Bellavita, P., Fenili, D., et al.: Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann. Intern. Med., 1992, 117(7), 573–577.
Younis, L. K., Talaat, F. M., Deif, A. H., et al.: Immunohistochemical detection of HCV in nerves and muscles of patients with HCV associated peripheral neuropathy and myositis. Int. J. Health Sci. (Qassim), 2007, 1(2), 195–202.
Gemignani, F., Brindani, F., Alfieri, S., et al.: Clinical spectrum of cryoglobulinaemic neuropathy. J. Neurol. Neurosurg. Psychiatry, 2005, 76(10), 1410–1414.
Casato, M., Saadoun, D., Marchetti, A., et al.: Central nervous system involvement in hepatitis C virus cryoglobulinemia vasculitis: a multicenter case-control study using magnetic resonance imaging and neuropsychological tests. J. Rheumatol., 2005, 32(3), 484–488.
Palazzi, C., D’Angelo, S., Olivieri, I.: Hepatitis C virus-related arthritis. Autoimmun. Rev., 2008, 8(1), 48–51.
Kemmer, N. M., Sherman, K. E.: Hepatitis C-related arthropathy: Diagnostic and treatment considerations. J. Musculoskelet. Med., 2010, 27(9), 351–354.
McGuire, B. M., Julian, B. A., Bynon, J. S. Jr., et al.: Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann. Intern. Med., 2006, 144(10), 735–741.
Aref, S., Sleem, T., El Menshawy, N., et al.: Antiplatelet antibodies contribute to thrombocytopenia associated with chronic hepatitis C virus infection. Hematology, 2009, 14(5), 277–281.
Lakatos, M., Hagymási, K., Lengyel G.: Fatty liver and hepatitis C virus infection. [A májzsírosodás és a hepatitis C-vírus-fertőzés.] Orv. Hetil., 2011, 152(38), 1513–1519. [Hungarian]
Adinolfi, L. E., Rinaldi, L., Guerrera, B., et al.: NAFLD and NASH in HCV infection: Prevalence and significance in hepatic and extrahepatic manifestations. Int. J. Mol. Sci., 2016, 17(6), 803.
Cheng, Z., Zhou, B., Shi, X., et al.: Extrahepatic manifestations of chronic hepatitis C virus infection: 297 cases from a tertiary medical center in Beijing, China. Chin. Med. J. (Engl.), 2014, 127(7), 1206–1210.
Narita, R., Abe, S., Kihara, Y., et al.: Insulin resistance and insulin secretion in chronic hepatitis C virus infection. J. Hepatol., 2004, 41(1), 132–138.
Lonardo, A., Adinolfi, L. E., Petta, S., et al.: Hepatitis C and diabetes: the inevitable coincidence? Expert Rev. Anti Infect. Ther., 2009, 7(3), 293–308.
Gastaldi, G., Goossens, N., Clément, S., et al.: Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review. J. Adv. Res., 2017, 8(2), 149–159.
Akeno, N., Blackard, J. T., Tomer, Y.: HCV E2 protein binds directly to thyroid cells and induces IL-8 production: a new mechanism for HCV induced thyroid autoimmunity. J. Autoimmun., 2008, 31(4), 339–344.
Ohoka, S., Tanaka, Y., Amako, Y., et al.: Sialadenitis in patients with chronic hepatitis C is not directly related to hepatitis C virus. Hepatol. Res., 2003, 27(1), 23–29.
Himoto, T., Masaki, T.: Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection. Clin. Dev. Immunol., 2012, 2012, 871401.
Antonelli, A., Ferri, C., Fallahi, P.: Thyroid cancer in patients with hepatitis C infection. JAMA, 1999, 281(17), 1588.
Blackard, J. T., Kong, L., Huber, A. K., et al.: Hepatitis C virus infection of a thyroid cell line: implications for pathogenesis of hepatitis C virus and thyroiditis. Thyroid, 2013, 23(7), 863–870.
Voulgaris, T., Sevastianos, V. A.: Atherosclerosis as extrahepatic manifestation of chronic infection with hepatitis C virus. Hepat. Res. Treat., 2016, 2016, 7629318.
Wong, R. J., Kanwal, F., Younossi, Z. M., et al.: Hepatitis C virus infection and coronary artery disease risk: a systematic review of the literature. Dig. Dis. Sci., 2014, 59(7), 1586–1593.
Boddi, M., Abbate, R., Chellini, B., et al.: HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques. Dig. Liver Dis., 2007, 39(Suppl. 1), S55–S60.
Quansah, R., Cooper, C. J., Said, S., et al.: Hepatitis C- and HIV-induced porphyria cutanea tarda. Am. J. Case Rep., 2014, 15, 35–40.
Cacoub, P., Poynard, T., Ghillani, P., et al., for the MULTIVIRC GROUP: Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum., 1999, 42(10), 2204–2212.
Zegans, M. E., Anninger, W., Chapman, C., et al.: Ocular manifestations of hepatitis C virus infection. Curr. Opin. Ophthalmol., 2002, 13(6), 423–427.
Fletcher, N. F., McKeating, J. A.: Hepatitis C virus and the brain. J. Viral Hepatol., 2012, 19(5), 301–306.
Yarlott, L., Heald, E., Forton, D.: Hepatitis C virus infection, and neurological and psychiatric disorders – A review. J. Adv. Res., 2017, 8(2), 139–148.
Khosla, S., Hassoun, A. A., Baker, B. K., et al.: Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults. J. Clin. Invest., 1998, 101(10), 2165–2173.
Rosenthal, E., Cacoub, P.: Extrahepatic manifestations in chronic hepatitis C virus carriers. Lupus, 2015, 24(4–5), 469–482.
Ramos-Casals, M., Zignego, A. L., Ferri, C., et al., on behalf of the International Study Group of Extrahepatic Manifestations related to HCV (ISG-EHCV): Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. J. Hepatol., 2017 Feb 27. doi: http://dx.doi.org/10.1016/j.jhep.2017.02.010 [Epub ahead of print]
Monti, G., Saccardo, F., Rinaldi, G., et al.: Colchicine in the treatment of mixed cryoglobulinemia. Clin. Exp. Rheumatol., 1995, 13(Suppl. 13), S197–S199.
Saadoun, D., Rosenzwajg, M., Joly, F., et al.: Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med., 2011, 365(22), 2067–2077.